M2 PHARMA-August 16, 2017-Halloran Consulting to Act as US Regulatory Lead for Curtana Pharmaceuticals' CT-179 Orphan Drug Designation for the Treatment of Gliomas
US-based biotech, pharma, and medical device consultancy Halloran Consulting Group has assumed the role of US regulatory consultants for US-based Curtana Pharmaceuticals, the firm said.
The Food and Drug Administration granted orphan drug designation to CT-179, Curtana Pharmaceuticals' lead Olig2 inhibitor for the treatment of gliomas, including glioblastoma in adults and pediatric high grade glioma in children.
Curtana Pharmaceuticals received orphan drug designation for CT-179 from the FDA after a review period of only 19 days.
The Food and Drug Administration (FDA) has granted orphan drug designation to CT-179, Curtana Pharmaceuticals' lead Olig2 inhibitor for the treatment of gliomas, including glioblastoma (GBM) in adults and pediatric high gra de glioma in children.
Curtana is targeting Olig2, a transcription factor important to normal brain development that has been shown to be a critical oncogene controlling tumor initiation, growth, invasion, differentiation and radiation resistance.
and Chief Executive Officer, Curtana Pharmaceuticals.
Curtana Pharmaceuticals, founded in 2013, is a privately held, preclinical-stage biopharmaceutical company headquartered in Austin, Texas.
Henry Riding, prosecuting, said Wilde, of Curtana
Crescent, Norris Green, was stopped at a security check at the prison as the metal detector alarm sounded.
At the core of Modulant Curtana is a patent-pending methodology that formalizes, captures, and incorporates the meaning, context, and structure of data into a consistent, unified definition of information that is interoperable among disparate applications.
A protocol- and transport-neutral interoperability solution, Modulant Curtana remains separate from applications and data sources, thereby minimizing the time, expense, and risk involved in implementing and maintaining interoperability.
With the commercial availability of the Modulant Curtana platform, Modulant is licensing its software through a distribution network of global systems integrators and IT consulting firms.